Dihexa vs Pinealon
Both Dihexa and Pinealon are used for cognitive. Here's how their evidence, dosing, and regulatory status actually compare.
Dihexa
Evidence CDihexa (PNB-0408)
An angiotensin IV-derived hexapeptide that mimics hepatocyte growth factor (HGF)/c-Met signaling and produced rapid synaptogenesis in animal models. No human trials.
View full Dihexa profile →Pinealon
Evidence CPinealon (EDR)
A short tripeptide developed in Russia for cognitive aging and oxidative stress. Limited Western clinical evidence.
View full Pinealon profile →Side-by-Side
| Attribute | Dihexa | Pinealon |
|---|---|---|
| Evidence Grade | C | C |
| FDA Status | Not FDA-approved — research compound (HGF/c-Met-mimetic) | Not FDA-approved — Russian-origin research peptide |
| Typical Dose | 8–45 mg orally daily (research-only) | 5–10 mg daily for 10–20 days (subcutaneous, cycled) |
| Clinics Indexed | 10 | 9 |
| Categories | cognitive, neuroprotection | cognitive, longevity |
Key reported benefits — Dihexa
- ✓Synaptogenesis (preclinical)
- ✓Memory improvement (animal)
- ✓Possible Alzheimer's relevance
Key reported benefits — Pinealon
- ✓Cognitive function (preclinical)
- ✓Reduced oxidative damage
- ✓Sleep/circadian effects
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.